X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ponatinib (278) 278
index medicus (176) 176
humans (147) 147
oncology (117) 117
imatinib (111) 111
chronic myeloid leukemia (85) 85
dasatinib (76) 76
hematology (75) 75
chronic myeloid-leukemia (68) 68
leukemia (66) 66
mutation (62) 62
nilotinib (61) 61
tyrosine kinase inhibitor (55) 55
tyrosine kinase inhibitors (55) 55
protein kinase inhibitors - pharmacology (54) 54
resistance (50) 50
protein kinase inhibitors - therapeutic use (49) 49
female (48) 48
male (48) 48
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (47) 47
animals (46) 46
chronic myelogenous leukemia (44) 44
bosutinib (43) 43
cancer (43) 43
bcr-abl (42) 42
hemic and lymphatic diseases (41) 41
imidazoles - pharmacology (41) 41
tyrosine (41) 41
middle aged (39) 39
antineoplastic agents - therapeutic use (37) 37
pyridazines - pharmacology (36) 36
kinases (35) 35
cml (34) 34
fusion proteins, bcr-abl - genetics (34) 34
antineoplastic agents - pharmacology (33) 33
imidazoles - therapeutic use (33) 33
philadelphia chromosome (33) 33
adult (32) 32
therapy (32) 32
analysis (31) 31
genetic aspects (31) 31
pharmacology & pharmacy (31) 31
mice (30) 30
mutations (30) 30
ap24534 (29) 29
pyridazines - therapeutic use (29) 29
cell line, tumor (28) 28
chemotherapy (28) 28
leukemia, myelogenous, chronic, bcr-abl positive - genetics (28) 28
article (27) 27
apoptosis (25) 25
drug resistance (25) 25
drug resistance, neoplasm - genetics (25) 25
care and treatment (24) 24
chromosome-positive leukemias (24) 24
medicine & public health (24) 24
aged (23) 23
bcr-abl inhibitor (22) 22
imatinib mesylate (22) 22
research (22) 22
patients (21) 21
stem cells (21) 21
drug resistance, neoplasm - drug effects (20) 20
fusion proteins, bcr-abl - antagonists & inhibitors (20) 20
inhibitor (20) 20
protein kinase inhibitors - adverse effects (20) 20
inhibitors (19) 19
acute lymphoblastic leukemia (18) 18
cell proliferation - drug effects (18) 18
protein kinase inhibitors - administration & dosage (18) 18
biochemistry & molecular biology (17) 17
cell biology (17) 17
chromosomes (17) 17
protein-tyrosine kinase (17) 17
protein-tyrosine kinases - antagonists & inhibitors (17) 17
xenograft model antitumor assays (17) 17
drug resistance, neoplasm (16) 16
gene mutations (16) 16
health aspects (16) 16
imidazoles - administration & dosage (16) 16
pyridazines - administration & dosage (16) 16
acute lymphoblastic-leukemia (15) 15
chemistry, medicinal (15) 15
myeloid leukemia (15) 15
proteins (15) 15
research paper (15) 15
t315i mutation (15) 15
cancer research (14) 14
clinical trials (14) 14
follow-up (14) 14
fusion proteins, bcr-abl - metabolism (14) 14
imidazoles - adverse effects (14) 14
neoplasms (14) 14
pyridazines - adverse effects (14) 14
safety (14) 14
tumors (14) 14
apoptosis - drug effects (13) 13
cells (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - pathology (13) 13
mechanisms (13) 13
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (282) 282
French (6) 6
Korean (2) 2
Czech (1) 1
Japanese (1) 1
Polish (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 62, pp. 31958 - 31970
Angiogenesis is a hallmark for cancer development because it is essential for cancer growth and provides the route for cancer cell migration (metastasis).... 
Angiogenesis | HUVEC | MAPK | Ponatinib | ENOS
Journal Article
Annales de Dermatologie et de Venereologie, ISSN 0151-9638, 11/2018, Volume 145, Issue 11, pp. 665 - 670
Background: Pityriasis rubra pilaris (PRP) is a cutaneous syndrome of unknown origin. Most cases are sporadic and acquired. Herein we report a fifth case of... 
Tyrosine kinase inhibitor | Pityriasis rubra pilaris | Ponatinib
Journal Article
Leukemia Research, ISSN 0145-2126, 06/2019, Volume 81, pp. 102 - 104
Journal Article
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, ISSN 1386-1425, 05/2019, Volume 214, pp. 199 - 206
Binding of a potent anticancer agent, ponatinib (PTB) to human serum albumin (HSA), main ligand transporter in blood plasma was analyzed with several spectral... 
Human serum albumin | Drug-protein interaction | Ponatinib | Molecular docking | Fluorescence quenching | INHIBITOR PONATINIB | LIGAND-BINDING | MECHANISM | STABILITY | BCR-ABL | ENZYMATIC-PROPERTIES | FLUORESCENCE | SPECTROSCOPY | WARFARIN | PRACTICAL ASPECTS | PROTEINS | Thermodynamics | Hydrogen | Analysis | Bonds | Albumin | Fluorescence | Anticoagulants (Medicine) | Methods | Protein binding | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2019, Volume 62, Issue 6, pp. 2905 - 2915
Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19... 
DOSE-ESCALATION | PONATINIB | CHEMISTRY, MEDICINAL | COVALENT INHIBITORS | FGF19 | JNJ-42756493 | PHASE-I | FIBROBLAST-GROWTH-FACTOR-19 | EXPRESSION | DISCOVERY | INSIGHTS
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2019, Volume 187, Issue 1, pp. e15 - e17
Journal Article
Actualités pharmaceutiques, ISSN 0515-3700, 06/2017, Volume 56, Issue 567, pp. 1 - 5
De nombreux médicaments en cancérologie obtiennent chaque année une autorisation de mise sur le marché, particulièrement les thérapeutiques antinéoplasiques... 
trametinib | ponatinib | tramétinib | cancérologie | oncology
Journal Article
Oncotarget, ISSN 1949-2553, 05/2018, Volume 9, Issue 41, pp. 26491 - 26506
In recent years, numerous new targeted drugs, including multi-kinase inhibitors and epigenetic modulators have been developed for cancer treatment. Ponatinib... 
DBET1 | Drug combination | JQ1 | Ponatinib | BRD4 degrader
Journal Article
LEUKEMIA & LYMPHOMA, ISSN 1042-8194, 08/2017, Volume 58, Issue 8, pp. 2005 - 2007
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 10/2016, Volume 9, Issue 10, pp. 923 - 932
Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder that has become the neoplastic poster child for understanding the disease biology... 
Ponatinib | chronic myeloid leukemia | tyrosine kinase inhibitor | SAFETY | FOLLOW-UP | BCR-ABL INHIBITOR | TYROSINE KINASE INHIBITORS | RESISTANT | PHARMACOKINETICS | AP24534 | IMATINIB | BOSUTINIB | HEMATOLOGY | IDENTIFIES PONATINIB
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 212, pp. 109 - 118
The establishment of imatinib as the standard therapy for CML marked the beginning of a new era of treatment. Due to occurring intolerance and resistance... 
Ponatinib | Tyrosine kinase inhibitor (TKI) | CML
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2017, Volume 179, Issue 3, pp. 497 - 498
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 2, pp. 254 - 258
Ponatinib, a novel tyrosine kinase inhibitor marketed in 2016, is a key drug used for treating chronic myeloid leukemia and Philadelphia chromosome-positive... 
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018
Ponatinib, a novel tyrosine kinase inhibitor marketed in 2016, is a key drug used for treating chronic myeloid leukemia and Philadelphia chromosome-positive... 
high-performance liquid chromatography equipped with ultraviolet detection method | human plasma concentration | ponatinib | bosutinib
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.